Crispr Therapeutics Ag (CRSP)
$85.90 0.76 (0.89%)
19:55 EDT CRSP Stock Quote Delayed 30 Minutes
Previous Close $85.90
Market Cap 4.02B
PE Ratio -
Volume (Avg. Vol.) 643,300
Day's Range 83.40 - 87.71
52-Week Range 32.30 - 105.12
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
- From InvestorPlace
- From the Web
CRSP stock has pulled back 13% in the last two sessions — on no news. The dip allows investors into a strong long-term story at a lower price.
We're still very early in the development of gene editing, and CRISPR Therapeutics is one of the first out of the block. But it's not hte final word.
By Alex Sirois
Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.
Patient investors can finally receive their rewards if Crispr Therapeutics makes good on its gene-editing breakthrough. However, you've got to be in CRISPR stock before this occurs.
CRSP stock may arouse some controversy. However, the underlying biotech firm’s profound potential to improve the human condition is worth taking a shot.
Experimental genetic treatments could hold the key to a better quality of life for patients and long-term returns for CRISPR stockholders.
Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.
These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
It's no secret Matt McCall is searching for emerging trends. This week, he discusses cannabis stocks and a breakthrough biotech therapy.
CRISPR is a great addition to your stock wish list. If we get a correction, this is a solid long-term addition to your portfolio.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
From Seeking Alpha
Centene (CNC +3.9%) is leading almost all insurers & managed care firms 2 1/2 hours into the session after it reiterated its 2020 non-GAAP EPS guidance of $4.76 - 4.96 that it released in July that included a modest cut in projected revenue. Consensus outlook is non-GAAP EPS of $4.88 on revenue of $110.57B.Selected tickers: CVS Health (CVS +1.1%), eHealth (EHTH +3.9%), UnitedHealth Group (UNH +2.8%), Triple-S Management (GTS +2.2%), Molina Healthcare (MOH +5.0%), Humana (HUM +3.4%), Cigna (CI +1.8%), Anthem (ANTM +3.6%)
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader